Humoral immune durability of IgG for anti-SARS-CoV-2 in the normal pregnant women in Wuhan, China
Tài liệu tham khảo
Maine GN, Lao KM, Krishnan SM, Afolayan-Oloye O, Fatemi S, Kumar S, VanHorn L, et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol. 2020;133:104663.
Lumley SF, Eyre DW, McNaughton AL, Howarth A, Hoosdally S, Hatch SB, Kavanagh J, et al. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Euro Surveill. 2020;25(24):2001721.
Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194.
China NHC. New Coronavirus Pneumonia Prevention and Control Protocol. 7th ed. National Health Commission of the People’s Republic of China; 2020. Accessed 4 March 2020.
He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397:1075–84.
Vojtek I, Dieussaert I, Doherty TM, Franck V, Hanssens L, Miller J, Bekkat-Berkani R, et al. Maternal immunization: where are we now and how to move forward? Ann Med. 2018;50:193–208.